In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Determinants of participation and risk factor control in coronary patients attending cardiovascular rehabilitation programme: Results from EUROASPIRE IV survey

Session Time to go to rehab - Best of cardiac rehabilitation

Speaker Kornelia Kotseva

Congress : ESC Congress 2017

  • Topic : preventive cardiology
  • Sub-topic : Rehabilitation: Outcomes
  • Session type : Moderated Posters
  • FP Number : P4910

Authors : K Kotseva (London,GB), D De Bacquer (Gent,BE), D Wood (London,GB)

Authors:
K. Kotseva1 , D. De Bacquer2 , D. Wood1 , 1National Heart and Lung Institute, Imperial College London - London - United Kingdom , 2Ghent University - Ghent - Belgium ,

On behalf: EUROASPIRE IV Investigators

Citation:
European Heart Journal ( 2017 ) 38 ( Supplement ), 1031-1032

Background: The EUROASPIRE IV survey was a cross-sectional study undertaken in coronary patients in 78 centres from 24 European countries.

Purpose: To describe the determinants of participation and achievement of risk factor targets in coronary patients attending a cardiovascular rehabilitation programme (CRP).

Methods: Consecutive patients aged <80 years with acute coronary syndromes and/or revascularization procedures were identified from hospital records and interviewed and examined at least 6 months after their recruiting event.

Results: A total of 7998 patients (24% females) were interviewed on average 16 months after having experienced a cardiac event. Overall, 51% of patients were advised to participate in a CRP and 81% of them attended at least half of the sessions; being only 41% of the whole study population. Older patients, women, those at low socio-economic status or enrolled with percutaneous coronary intervention (PCI) and unstable angina, as well as those with a previous history of coronary disease, heart failure, hypertension or dysglycaemia received less advice to follow a CRP. Patients recruited after CABG and AMI were more likely to get such advice. People smoking in the month prior to the recruiting event did participate much less in a CRP, if advised. The proportions of patients achieving lifestyle targets were higher in the CRP group as compared to the non-CRP group: stopping smoking (57% vs 47%, p<0.0001), recommended physical activity levels (47% vs 38%, p<0.0001) and BMI <30 kg/m2 (65% vs 61%, p=0.0007). However, there were no differences in terms of management of blood pressure, lipids and controlled HbA1c levels in patients with diabetes.

Conclusions: Just over 40% of coronary patients reported attending a CRP. Although the control of smoking, obesity and physical activity was better in those attended a CRP there were no differences in terms of blood pressure, lipids and glucose management. There is an urgent need of comprehensive, multidisciplinary prevention programmes addressing all aspects of the lifestyle, other risk factors and therapeutic management for all patients with coronary or other atherosclerotic disease.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are